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Scutellaria barbata (S. barbata), a Chinese herb used in Traditional Chinese Medicine has 
been known to contain anti-cancer properties. SB has been investigated as a potential treatment 
for multiple types of cancer including colon cancer, glioblastoma, and ovarian cancer. Breast 
cancer cell lines MDA-MB-157 and its APC-mutants 93A and 93B are more resistant to 
treatment due to genetic modifications. In this study, the effectiveness of S. barbata in apoptotic 
modulation of breast cancer cell lines MDA-MB-157, 93A, and 93B was investigated. 
Assessments were performed using green/red/blue fluorescent Apoptosis/Necrosis Detection Kit 
and the Human Apoptosis Antibody Array - Membrane (43 Targets) test by the Abcam 
corporation. Our data demonstrated that 1-hour and 3-hour treatments with 2 mg aqueous extract 
of S. barbata induced a statistically significant percentage of apoptosis in all cell lines. 
Additionally, modulation of various apoptotic markers such as pro-apoptotic proteins Bad, Bax, 














Cancer is one of the leading causes of deaths each year. Breast cancer is the second most 
common cancer in American women, and the second leading cause of cancer death (American 
Cancer Society, 2021). Statistics show that 1 in about 8 women in the United States will develop 
invasive breast cancer in her lifetime (Breastcancer.org, 2021). Even though many cancer 
treatments are now available, most of them are invasive, affecting the quality of life of those 
suffering from the disease. Known treatments for cancer such as radiation therapy and 
chemotherapy may cause severe side effects and drug resistance (Dai et al., 2013). In addition, 
patients may also accumulate toxins and suffer from compromised immune systems after the 
treatments.  
Breast cancer was the most common type of cancer in the United States in 2019. There 
were about 271,270 cases and 41,760 deaths that year, as published by the American Cancer 
Society. By the end of 2021, there is a projected estimate of 281,550 new cases and 43,600 
deaths. These elevated numbers clearly show that there is a need for new methods of research. 
Therefore, it is worthwhile to investigate novel anti-cancer compounds.  
Traditional Chinese Medicine, which focuses on the use of herbs for disease treatment 
has been widely used in Asia for over two thousand years. It focuses on the use of herbs for 
many medical problems, including stroke, heart disease, mental disorders, and respiratory 
diseases. Nonetheless only in the last few decades have those herbs been studied by Western 
medicine for their anti-cancer properties (Ye L., et al., 2015).  As a result of the increased 
interest in research, multiple herbs have been found to possess biologically active compounds 
known as phytochemicals, which have anti-cancer characteristics (Dai et al., 2013). There are 
two main molecular bases through which these phytochemicals are known to act against cancer: 
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triggering apoptosis of cancer cells (guided multi-step pathway that ultimately causes cell death) 
and by inhibiting angiogenesis (formation of new blood vessels within tumors) (Parekh, Liu, & 
Wei, 2009). Thus, there is interest in developing less invasive remedies obtained from Chinese 
herbs, which are usually administered by teas and are known to have less toxicity than current 
drugs and cancer treatments (Perez et al., 2010).  
Scutellaria barbata (S. barbata), is one of the herbs used in Traditional Chinese 
Medicine for removal of toxic materials, improving circulation, removing blood stasis, and 
reducing edema in the body. More recently, research has provided evidence for anti-cancer and 
anti-inflammation properties (Chen, Rahman, Wang, Zhou, & Zhang, 2020). As a result, S. 
barbata has been investigated as a potential treatment for multiple types of cancer including 
colon cancer, lung cancer, ovarian cancer and breast cancer (Dai et al., 2013). Typically, these 
studies use aqueous extracts from S. barbata followed by screening for anti-cancer properties 
against multiple cell lines. Extracts from S. barbata induced apoptosis in proliferating ovarian 
cancer cell lines in vitro (Powell et al., 2003) and effectively inhibited growth rate of hepatoma 
in mice (Li et al., 2019). A study comparing the effectiveness of extracts of twelve different 
Chinese herbs against human cancer cell lines, found that S. barbata showed specificity towards 
growth inhibition of breast cancer cells. In addition, extracts of S. barbata have demonstrated 
both antiproliferative activity as well as anti-cancer effects against lung, pancreas and prostate 
cancer (Shoemaker M., et al, 2005). On prior years, Dr. Wong’s lab studied cell survival in 
TRAMP mice finding that S. barbata modulated apoptosis on both murine and human prostate 
cancer cells (Wong, B. Y., et. al, 2009).  
Breast cancer cell lines MDA-MB-157 and its APC-mutants (93A and 93B) have been 
genetically modified by the Harper Cancer Research Institute in collaboration with Indiana 
University School of Medicine so that they can be resistant to treatment due to inhibition of the 
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APC tumor suppressor gene. Normal function of the APC protein is to keep cells from growing 
and dividing too fast or in an uncontrolled way (VanKlompenberg, M. K., et al, 2004).  
  In an effort to comprehend the anti-cancer properties of S. barbata, This study uses said 
cell lines in order to investigate and understand the apoptotic effect that the aqueous extract has. 
Two experimental procedures were performed. The first one was the Apoptosis and Necrosis 
Detection Kit via fluorescent microscopy. The purpose of this procedure was to stain the cancer 
cells with three different fluorescent markers, which provided differentiation between apoptotic, 
necrotic and live cell. Apopxin green dye binds to cancer cells displaying the lipid molecule 
Phosphatidylserine (a known apoptotic marker presents on the outside of the cell membrane), 
which causes green fluoresce and indicate apoptosis. 7-ADD binds to the nucleus of cells that 
have undergone necrosis (late stage of apoptosis) and do not have membrane integrity, causing 
red fluoresce. Finally, CytoCalcein violet 450 binds to the cytoplasm of live and normal cancer 
cells causing blue fluoresce. Blue cells indicate treatment ineffectiveness. Each cell line was 
divided into a negative control group (distilled water added), positive control group 
(Staurosporine added) and treatment group (S. barbata extract added). Once protocol was 
completed, the results were analyzed through fluorescent microscopy. This methodology allowed 
for the analysis of the effectiveness of the S. barbata extract in comparison to a known apoptotic 
agent.  
The second experimental procedure was the Human Apoptosis Antibody Array – (43) 
Membrane detection. Some of the regulatory functions in apoptosis are ascribed to internal 
signals from the Bcl-2 family of proteins which include Bad, Bax, Bid, Bim, among others. 
These proteins interact with each other activating the downstream pathway of apoptosis. Some of 
the proteins are characterized as anti-apoptotic (inhibiting apoptosis), while others are pro-
apoptotic (promoting cell death) (Table 1). By using the 43 Apoptotic Marker Membrane Array, 
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which contains specific antibodies for said proteins, quantification for levels of protein 
expression was possible. The signal intensity for each antigen-specific antibody is proportional 
to the concentration of protein in that sample. As a result, comparison of signal intensities seen 
as darkness and size differences in the membranes can be quantified by taking X-ray images, 
digitalizing them and using ImageJ to measure signal absorbances. Said procedure allowed for 
values to be compared among positive, negative and control group for each cell line in order to 
determine significant differences in anti-apoptotic and pro-apoptotic protein expression. 
Therefore, determining the apoptotic modulation effect of S. barbata on cell lines MDA-MB 
157, 93A and 93B.  
The findings from this research will aid in the understanding of apoptosis on resistant 
breast cancer cell lines MDA-MB 157, 93A and 93B for which not much information has been 
collected. In addition, the modulation of various pro-apoptotic and anti-apoptotic proteins by S. 
barbata will be studied, providing an insight on how the phytochemicals in the herb act in 
promoting the action of specific apoptotic proteins.  
 
Table 1. Function and description of the 43 proteins found in Human Apoptosis Antibody Array 
membrane.  
 
Protein Function Description 
Bcl-2 anti-apoptotic BCL2 (and its antiapoptotic orthologues, BCL-XL and BCL-W) seems to inhibit apoptosis by the 
preservation of mitochondrial mem- brane integrity as its hydrophobic carboxyl-terminal domain is 
linked to the outer membrane. BCL2 prevents BAX/BAK oligomerization, which would otherwise 
lead to the release of several apoptogenic molecules from the mitochondrion.  (Tzifi et al., 2012) 
Bcl-w anti-apoptotic BCL2 (and its antiapoptotic orthologues, BCL-XL and BCL-W) seems to inhibit apoptosis by the 
preservation of mitochondrial mem- brane integrity as its hydrophobic carboxyl-terminal domain is 
linked to the outer membrane. BCL2 prevents BAX/BAK oligomerization, which would otherwise 
lead to the release of several apoptogenic molecules from the mitochondrion.  (Tzifi et al., 2012) 
cIAP-2 anti-apoptotic cIAP2 has been demonstrated to inhibit cell death by directly repressing the proapoptotic activity of 
a family of cysteine proteases (25), caspases, as well as targeting proapoptotic components of the 
TNF-α signaling pathway for ubiquitin degradation 
(Tzifi et al., 2012) 
Fas anti-apoptotic FASL-FAS signaling triggers apoptosis through FADD (Fas-associated protein with death domain, 
also called MORT1) adaptor protein-mediated recruitment and activation of the aspartate-specific 
cysteine protease, caspase-8.  
(Strasser, Jost, & Nagata, 2009)  
FasL anti-apoptotic FASL-FAS signaling triggers apoptosis through FADD (Fas-associated protein with death domain, 
also called MORT1) adaptor protein-mediated recruitment and activation of the aspartate-specific 
cysteine protease, caspase-8.  (Strasser et al., 2009)  
HSP27 anti-apoptotic The role of Hsp27 in apoptosis is inhibition of apoptosome formation.  
(Takayama, Reed, & Homma, 2003)  
HSP60 anti-apoptotic Hsp60 is a heat-shock protein that primarily localizes to the matrix of the mitochondria. Reduction 
in HSP60 expression precipitates apoptosis 
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(Takayama et al., 2003)  
HSP70 anti-apoptotic Hsp70 directly binds to apoptosis-inducing factor (AIF), inhibiting AIF-dependent apoptosis. 
(Takayama et al., 2003)  
IGF-I anti-apoptotic The main focal point of IGF-I is the regulation of Bcl-2 family proteins acting as an inhibitor of 
apoptosis in many different cell types. (Kooijman, 2006) 
IGF-II anti-apoptotic This protein plays an essential role in growth and development before birth. Studies suggest that 
insulin-like growth factor 2 promotes the growth and division (proliferation) of cells in many 
different tissues. 
https://medlineplus.gov/genetics/gene/igf2/ 
IGFBP-1 anti-apoptotic  IGFBP1 protein localizes to mitochondria where it binds to the proapoptotic protein BAK and 
hinders BAK activation and apoptosis induction.  
(Leu & George, 2007) 
IGFBP-2 anti-apoptotic GFBP-2 regulates caspase-3 expression and contributes to the inhibitory effect on apoptosis 
independent of IGF. (Migita et al., 2010) 
IGF-1sR anti-apoptotic Insulin and IGF-1 binding stimulate receptor tyrosine kinase activity and blocks apoptosis. (Boucher 
et al., 2010) 
Livin anti-apoptotic Livin is a member of the inhibitors of apoptosis (IAP) family, which plays crucial roles in apoptosis, 
cell proliferation, and cell cycle control. 
(Yan, 2011) 
p21 anti-apoptotic p21 induction primarily inhibits apoptosis by causing cell cycle arrest and DNA repair.  (Abcam)  
Survivin anti-apoptotic Survivin, a member of the inhibitor of apoptosis (IAP) protein family that inhibits caspases and 
blocks cell death (Jaiswal, Goel, & Mittal, 2015) 
TRAILR-3 anti-apoptotic Inhibits apoptosis; however not much about its mechanism is known 
TRAILR-4 anti-apoptotic Inhibits apoptosis; however not much about its mechanism is known 
XIAP anti-apoptotic X-chromosome-linked inhibitor of apoptosis protein (XIAP) inhibits caspases and blocks apoptosis 
((Chaudhary et al., 2016) 
Bad pro-apoptotic BAD is released upon dephosphorylation [34]. BAD molecule is also cleaved by caspases when 
apoptosis is induced by transforming growth factor β1. (Tzifi et al., 2012) 
Bax pro-apoptotic BAX protein is a monomeric protein in the cytosol, which integrates into the mitochondria during 
apoptosis and subsequently oligomerizes, resulting to the release of apoptogenic factors like 
cytochrome c and the activation of the caspase cascade. (Tzifi et al., 2012) 
BID pro-apoptotic BID is activated by caspase-8 cleavage and N-myristoylation to target mitochondria, where it 
activates BAX and BAK or is alternatively sequestered by antiapoptotic BCL2 members, preventing 
death. (Tzifi et al., 2012) 
BIM pro-apoptotic BIM is a peptide found to induce cytochrome c release from mitochondria in vitro. It is thought to 
trigger apoptosis by binding and therefore inactivating the antiapoptotic BCL2 relatives. (Tzifi et 
al., 2012) 
Caspase3 pro-apoptotic Caspase-3 is known as an executioner caspase in apoptosis because of its role in coordinating the 
destruction of cellular structures such as DNA fragmentation or degradation of cytoskeletal proteins. 
(Caspase, 3)  
Caspase 8 pro-apoptotic Plays a central role in the execution-phase of cell apoptosis. 
CD40 pro-apoptotic CD40 ligation leads to TRAF recruitment and activation of the NF-κB and AP-1 pathways. 
Activation of these transcription factors can promote proliferation or apoptosis in a signal and cell 
type specific manner. 
(Georgopoulos et al., 2006) 
CD40L pro-apoptotic CD40 ligation leads to TRAF recruitment and activation of the NF-κB and AP-1 pathways. 
Activation of these transcription factors can promote proliferation or apoptosis in a signal- and cell 
type-specific manner. 
(Georgopoulos et al., 2006) 
cytoC pro-apoptotic Mitochondrial cytochrome c (cyt c) has been found to have dual functions in controlling both 
cellular energetic metabolism and apoptosis. Through interaction with apoptoticprotease activating 
factors (Apaf), cyt c can initiate the activation cascade of caspases once it is released into the 
cytosol. 
(Cai, Yang, & Jones, 1998) 
DR6 pro-apoptotic DR6 was identified as a member of the TNF receptor-related death receptor family… and it was 
found that DR6 induces apoptosis when it is overexpressed 
(Zeng et al., 2012) 
HTRA pro-apoptotic The HtrA family proteins are serine proteases that are involved in important physiological 
processes, including maintenance of mitochondrial homeostasis, apoptosis and cell signaling.  
(Zurawa-Janicka, Skorko-Glonek, & Lipinska, 2010) 
IGFBP-3 pro-apoptotic Insulin-like growth factor binding protein-3 (IGFBP-3) has a role as a primary growth inhibitor, it 
has been shown to increase ceramide-induced apoptosis and to enhance both p53-dependent and 
p53-independent apoptosis 
(Williams et al., 2007) 
IGFBP-4 pro-apoptotic One of the IGF binding proteins called IGFBP-4 is well known for its growth inhibitory effect on 
several cancer cells in vitro. overexpression of IGFBP-4 on established subcutaneous cancer model 
can increase tumor apoptosis 
(Durai, Yang, Seifalian, Goldspink, & Winslet, 2007) 
IGFBP-5 pro-apoptotic Insulin-like growth factor binding protein-5 (IGFBP5) is important for cell growth control and the 
induction of apoptosis.  Silencing IGFBP5 with small interfering RNA significantly reduced 
apoptosis and suppressed the expression of caspase-3 in NRVMs.  
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(Leung et al., 2014) 
IGFBP-6 pro-apoptotic IGFBP-6 has recently been shown to have a number of IGF-independent actions, including 
promotion of apoptosis in some cells and inhibition of angiogenesis 
(Bach, 2015) 
p27 pro-apoptotic p27 inhibits cyclin-CDK complexes from phosphorylating histone H1. Furthermore, overexpression 
of p27 was found to prevent CDK activation and entry into the S phase of the cell cycle. (Abukhdeir 
& Park, 2008) 
p53 pro-apoptotic P53 can activate BAX, which lacks a clearly identifiable BH3 domain. (Tzifi et al., 2012) 
SMAC pro-apoptotic Smac/DIABLO is a mitochondrial protein that potentiates some forms of apoptosis, possibly by 
neutralizing one or more members of the IAP family of apoptosis inhibitory proteins. Smac has 
been shown to exit mitochondria and enter the cytosol during apoptosis triggered by UV- or γ-
irradiation. 
(Adrain, Creagh, & Martin, 2001) 
sTNF-R1 pro-apoptotic  TNF-alpha receptors. sTNFR1 exerts immunoregulatory functions by induction of apoptosis in 
monocytes through reverse signaling via transmembrane TNF-alpha. (Waetzig et al., 2005) 
sTNR-R2 pro-apoptotic 
(selective) 
TNF-alpha receptors. sTNFR2 exerts immunoregulatory functions by induction of apoptosis in 
monocytes through reverse signaling via transmembrane TNF-alpha. (Waetzig et al., 2005) 
TNF-a pro-apoptotic TNF's main function is to stimulate inflammation by turning on gene transcription through the 
IKK/NFκB and JNK/AP-1 signaling cascades. TNF also can trigger apoptosis through caspase-8 
(Varfolomeev & Ashkenazi, 2004) 
TNF-B pro-apoptotic TNF's main function is to stimulate inflammation by turning on gene transcription through the 
IKK/NFκB and JNK/AP-1 signaling cascades. TNF also can trigger apoptosis through caspase-8 
(Varfolomeev & Ashkenazi, 2004) 
TRAILR-1 pro-apoptotic TNF-related apoptosis-inducing ligand (TRAIL), is a protein functioning as a ligand that induces 
the process of cell death called apoptosis.  
TRAILR-2 pro-apoptotic TNF-related apoptosis-inducing ligand (TRAIL), is a protein functioning as a ligand that induces 






General cells preparation protocols used for both experimental procedures  
 Making Cell Media (500ml) 
- Work in hood and wipe all bottles with alcohol  
- Warm stock RPIM media, FBS and Pen/Strep in water bath  
- Obtain empty/clean bottles: 250ml and 50ml  
- Remove 50ml of stock RPIM and place into clean 50ml bottle 
- Add 50ml of FBS and 5ml of Pen/Strep to 500ml EMEM stock bottle  
- Gently mix/swirl bottle  
- Remove 250ml of media from stock EMEM bottle and place into clean 250ml bottle 
- Label and date all media  
Waste disposal: do NOT throw any antibiotics (Pen/Strep down the sink)  
Herbal extraction protocol (S. Barbata)  
- Weigh graduated flask 
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- Weigh 10g herb and place in graduated flask 
- Add 100ml of sterile H2O 
- Incubate at 56C for 1 hr  
- Filter with Kim wipe to remove debris  
- Centrifuge at 3000rpm (upstairs) 
- Take supernatant and filter through buchner funnel with filter paper into 500ml 
Erlenmeyer flask  
- Dry with rotovap, take dry weight and dissolve in H20 to appropriate concentration 
- Filter with sterile micro filter 
Thawing Cells 
- Place vial of cells in a beaker with water and place the beaker in a 37°C water bath. 
- When the cells are thawed, titrate with 3mL syringe. 
- Add the cells to a 60mm cell culture dish that has 5mL warm media (if cold, place media 
- in hot water bath at the same time as cells to warm) 
- Change the media after 24 hours. Make sure to use 5mL media. Observe cells in dish 
before and after changing media. Incubate. 
Changing Media 
- Place media in 37°C water bath 15 minutes before use. 
- Make sure to disinfect hood, media bottle, and pipets before use. 
- With a new pipet, collect the old media in cell dish and throw in waste container. 
- Take a new pipet and obtain 5mL new media and add to cells. Observe and incubate 
cells. 
Passage of Cell Monolayers 
- Place media and trypsin in 37°C water bath to warm before use. When warm, spray and 
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- wipe bottles with ethanol and dry before placing under hood. 
- Remove the media from cells with a sterile pipet. 
- Rinse the cells with 1mL phosphate buffer and remove quickly. 
- Use a new, sterile pipet to put 3mL fresh trypsin onto the cells. 
- Incubate cells for 5 minutes. 
- After incubation, titrate with a new pipet to break apart clumps. 
- After titrating, add twice as much new media as the trypsin (6mL). 
 
Part I: Apoptosis and Necrosis Detection Kit 
Modified from the Abcam protocol ab176749. The purpose of this procedure is to stain the 
cancer cells with three different fluorescent markers, which will provide differentiation between 
apoptotic, necrotic and live cells based on the color. For each cell line there will be a negative 
control (no treatment added), positive control (Staurosporine, a known potent agent that induces 
apoptosis added) and a treatment group (S. barbata extract added). 
Cell culture preparation:  
- Make cell media 
- Prepare aqueous herb extract through herbal extraction protocol  
- Thaw cells 
- Change media as often as needed  
- Passage of cell monolayers when enough cells have developed  
Divide Cells into Plates 
- Place media, phosphate buffer, and trypsin bottles in 37°C water bath 15 minutes 
- before use. 
- Remove media from cells with pipet and place in waste bucket. 
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- With a new pipet, add 1mL phosphate buffer to cells and rinse. Remove with pipet and 
- put in waste. 
- Add 1mL trypsin to cells and swirl plate. 
- Check for detaching under microscope. 
- Incubate 5 minutes. 
- Check for detachment. 
- Add 2mL media (twice amount of trypsin) to cells. 
- Titrate cells vigorously 7-8 times, avoiding air bubbles. 
- Split the cells into 3 different plates and label plates 1, 2, 3. 
- Add 6mL media onto each plate. 
Cell treatment and incubation: 
- Seed 5000 cells per well (200 μl). 12 wells per cell line.  
o 6 wells for 3-hour treatment and 6 wells for 1-hour treatment.  
o Within the 6 wells, 2 will be negative control, 2 will be positive control and 2 will 
be experimental group (figure 1).  
- Incubate well plate overnight at 37˚C. 
- Remove reagents for apoptosis from refrigerator. Warm them up to room temperature.  
- Change cell media for each cell line and start treatment for 3-hour treatment. 
- Add 10 μl of staurosporine to positive control group. 
- Add 10 μl of DI water to negative control group. 
- Add 5 μl of S. barbata extract to treatment group.  
- Incubate well plate for 2 hours at 37˚C. 
- Repeat steps 5-7 to start 1-hour treatment. 
- Incubate well plate for 1 hour at 37˚C. 
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- Drain cell media from wells. 
- Wash wells with 100 μl of assay buffer. 
- Turn off lights and add fluorescent markers. 
o Add 200 μl of assay buffer 
o Add 2 μl of Apopxin green 
o Add 1 μl of red 7-ADD 
o Add 1 μl of blue CytoCalcein violet 450 
- Wrap in tin foil and incubate in Styrofoam box for 60 minutes.  
- Wash wells two times with 100 μl assay buffer. Plate is ready for observation. 
- Use fluorescent microscope to take pictures of each well in the plate (figure 2).  
Data collection 
- For each cell line, a minimal number of 200 cells were counted per plate (experimental, 
positive and negative). Depending on their color, each cell was categorized as normal 
(blue), apoptotic (green), or necrotic (red).  
- Then, the means obtained were compared between the negative and treatment group 
using a paired t-test. Said analysis provided the evidence to know whether there was a 
significant increase of apoptotic cells on the treatment group (S. barbata added) in 
comparison to the negative control group. 
 
Part II: Human Apoptosis Antibody Array – (43) Membrane Protocol: 
Some of the regulatory functions in apoptosis are ascribed to internal signals from the 
Bcl-2 family of proteins. These proteins interact with each other activating the downstream 
pathway of apoptosis. By using the 43 Apoptotic Marker Membrane Array we are able to 
quantify levels of protein expression. The signal intensity for each antigen-specific antibody will 
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be proportional to the concentration of the antigen in that sample. As a result, comparison of 
signal intensities for individual antigen-specific antibody spots between and among array images 
will allow for measurement of the apoptotic affect that S. barbata has on each breast cancer cell 
line. 
Cell culture preparation:  
- Make cell media 
- Prepare aqueous herb extract through herbal extraction protocol  
- Thaw cells 
- Change media as often as needed  
- Passage of cell monolayers when enough cells have developed  
Divide Cells into Plates 
- Place media, phosphate buffer, and trypsin bottles in 37°C water bath 15 minutes 
- before use. 
- Remove media from cells with pipet and place in waste bucket. 
- With a new pipet, add 1mL phosphate buffer to cells and rinse. Remove with pipet and 
- put in waste. 
- Add 1mL trypsin to cells and swirl plate. Check for detaching under microscope. 
Incubate 5 minutes. 
- Check for detachment. 
- Add 2mL media (twice amount of trypsin) to cells. 
- Titrate cells vigorously 7-8 times, avoiding air bubbles. 
- Split the cells into 3 different plates and label plates 1, 2, 3. 




- Change media on the plates, adding 5mL new media onto each plate. 
- Add 200 μL SB to plate 1, 200 μL DI water to plate 2, and 200 μL apoptotic agent to 
plate 3.  
- Incubate plates for 3 hours. 
Cell lysate preparation 
- Wash cells 2 times with cold 1X PBS buffer. 
- Spin cells down for 10 minutes at 1500 rpm. 
- Remove remaining liquid from cell pellet. 
- Add 1X lysis buffer to cell pellet. Pipette cells up and down to resuspend cells. 
- Incubate at 4˚C for 30 minutes, with gentle rocking or shaking.  
- Spin down lysates at 14000 x g for 10 minutes. 
- Transfer supernatant to fresh microfuge tubes. 500 μl per tube.  
Protein Assay Dye 
- Make BSA 100ng/µL working protein solution:  take 14.4µL of BSA and add 985.6µL of 
DDH2O =100ng/µL. 
- Determine standard curve by placing the correct amounts of H2O, Dye & BSA into each 
cuvette. (Table 1).  
- Determination of protein concentration of the extracted lysate of your samples: 
o  Obtain 3 cuvettes for the lysate samples and label A, B, C. 
o Into each of the three cuvettes place 790µL H2O, 200µL protein assay dye, and 
10µL lysate (your extracted protein solution). Leave for 5 minutes. 
o  mix/gently titrate before measuring absorbance. 
- Measure absorbance at A595  
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o First measure cuvette 1 from standard curve as reference. 
o Measure remaining standard curve cuvettes and record absorbance. 
o Measure the three lysate sample cuvettes and record absorbance. 
o Plot data for standard curve: absorbance vs. concentration. 
- Membrane: 
o Repeat Process for each of the three cell lines samples. 
o Use equation given from standard curve (y=mx+b) and substitute y with the 
absorbance from the lysate sample in order to find protein concentration.  
o Solve for protein x (ng/µL) and convert to µg/µL. 
Blocking and Incubations  
- Place each membrane printed side up into the 8-well tray provided in the kit. 
-  Add 2 mL 1X Blocking Buffer to each membrane. Incubate at room temp for 30 min 
with gentle rocking or shaking to block the membrane surface. 
- Decant Blocking Buffer and add fresh 1.2mL of Blocking Buffer. Add X µL of sample 
(Blocking Buffer + X µL of sample calculated from Protein Assay). Incubate membranes 
overnight at 4˚ Celsius with gentle rocking or shaking. (Place the lid on the 8 well tray 
during overnight incubation). 
-  Aspirate samples from membranes and wash 3x for 5 min with 2 mL Wash Buffer I at 
RT, use fresh buffer for each wash.  
o Large Volume Wash to reduce background. 
- Add 20-30 mL of Wash Buffer I per membrane and wash at RT with gentle shaking or 
rocking for 30-45 min. Return membranes to the 8 well tray. 
- Wash 2x 5 min with 2 mL of 1X Wash Buffer II each at RT. Decant and use fresh wash 
buffer each time.  
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- Add 1 mL of 1X Biotin-conjugated Anti-Cytokines to each membrane. Incubate 
overnight at 4˚ Celsius with gentle rocking or shaking (Place the lid on the 8-well tray for 
overnight incubation to prevent evaporation). 
-  Aspirate (remove) Anti-Cytokine reagent with pipette. Repeat washes in step 4 and 5.  
- Add 1.5 mL of 1X Streptavidin-HRP and incubate at room temperature for 2 hours.  
- Repeat washes in step 4 and 5.  
-  Proceed with Chemiluminescent Detection protocol below or store membrane for 
detection at a later date.  
Chemiluminescence Detection 
- Place a plastic sheet (provided in the kit) on your benchtop. 
- Place one or more array membranes protein side up on the plastic sheet. Drain excess 
liquid by touching one edge to blotting paper on tissue paper.  
- Into a single, clean tube, add equal volumes of Detection Buffer C and Detection Buffer 
D immediately prior to detection. Mix well. Add 250 μl of each buffer per membrane to 
be detected. 
o For 9 membranes, combine 1 ml of each detection buffer.  
- Pipette the mixed Detection Buffers on to each membrane. Place another plastic sheet on 
top, gently smooth out any air bubbles. Incubate at room temperature for 2 minutes.  
- Remove top plastic sheet and remove excess liquid.  
- Gently replace the membranes (protein side up) on the bottom plastic sheet and replace 
the top plastic sheet with wrap. Gently smooth out any air bubbles on the membrane 
surfaces.  
- Detect signals exposing the array membranes to X-ray film and detect the signal using a 
film developer. 
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o Transfer the membrane, protein side down, to the plastic wrap. Fold the plastic 
wrap over well to completely cover the membrane.  
o Place a pre-cut piece of x-ray film over the membrane. Cut the top right corner of 
the film for orientation in the cassette. 
o Close the cassette an expose between 5 to 20 seconds. The signal rapidly 
decreases over time.  
o Remove x-ray film, dip in the developer until you see bands. 
o Wash by dipping in water container several times. 
o Place in the fixer for 3 min. 
o Wash by dipping in water container several times. 
o Hang by hook on wire until dry.  
- X-ray is ready for observation (Figure 1).  
 
Figure 1. Human Apoptosis Antibody Array X-ray film for Breast cancer cell line MDA-MB157 
Obtaining densitometry data 
- Scan X-ray film to obtain digitized image using an off-ice scanner with resolution of 
300dpi or greater.  
- Use densitometry software ImageJ to obtain spot signal densities from scanned images  
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- For each membrane identify single exposure that exhibit low background signal intensity 
and strong positive control signals that do not “bleed” into each other.  
- Measure the density of each spot using the Protein Array Analyzer plugin macro. 
o Obtain colored spot signal densities (Figure 2).  
- Once the raw densitometry data has been collected repeat procedure for each cell line 
membrane. 
 
Figure 2.  Human Apoptosis Antibody Array X-ray film with respective ImageJ software protein 
array analyzer results for Breast Cancer cell lines MDA-MB 157. 
 
Results 
Part I: Apoptosis and Necrosis Detection Kit 
Fluorescent apoptosis results (Figure 3) reveal that aqueous extract of SB induced a 
statistically significant percentage of apoptosis during 1-hour incubation in MDA-MB-157 (46.5 
± 7.5% > 16%± 1.0%, p < 0.05); 93A (54.5 ± 2.5% > 0%, p < 0.05); and 93 B (65.5 ± 13.5% > 
0%, p < 0.05).   
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Similar results were obtained with 3-hour incubation. MDA-MB-157 (65.5 ± 1.5% > 
28%± 1.0%, p < 0.05); 93A (71 ± 8% > 17 ±15%, p < 0.05); 93B (89 ± 1% > 16 ± 3%, p < 0.05).  
 
Figure 3.  Fluorescent microscopy pictures demonstrating 1-hour and 3-hour incubation results 
after treatment with 2mg of aqueous SB extract for cell lines (A) MDA-MB 157, (B) 93A and 
(C) 93B. Blue fluorescence indicates cytoplasm staining (normal live-cells), green fluorescence 
indicates inner phosphatidylserine exposure (apoptosis) and red fluorescence of the nucleus 
indicates loss of cell membrane (necrosis). 
 
Part II: Human Apoptosis Antibody Array – (43) Membrane Protocol 
Antibody Array Membrane ImageJ results for all cell lines (Figure 4) demonstrates that there 
was a statistically significant difference (p<0.05) between groups in the expression of the 
following pro-apoptotic proteins after analysis by one-way ANOVA (Table 2, 3, 4) and Tukey 
post hoc test: 
• MDA-MB-157:  BID (p=0.019) and BIM (p=0.007), IGFBP-4 (0.017), TNF-a (0.031) 
• 93A: Bad (p=0.02), BIM (p=0.001), C3(p=0.015), cytoC (0.030), IGFBP-3 (0.049), 
IGFBP-4 (0.014), IGFBP-6 (0.004), p53 (p=0.004) and sTNF-R2 (0.032).  
• 93B: All proteins except IGFBP-6 had p<0.05. Some of the most important values are 
Bad (p=0.002), Bax (p=0.020), BID (p=0.001), p27 (0.004), p53 (0.022). 
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Figure 4.  Human Apoptosis Antibody Array X-ray film with respective ImageJ software protein 
profiling analysis using color intensities to reveal spot signal densities of various apoptotic 
protein concentration for Breast Cancer cell lines (A) MDA-MB 157, (B) 93A and (C) 93B after 
treatment with 2mg SB. Some significant apoptotic proteins observed were: Bad, Bax, Bid, Bim, 
C3, C8, cytoC, DR6, HTRA, IGFBP-5, p27, p53, TNF-B, TRAILR-1, and TRAILR-2. 
 
















 Based on the quantitative values obtained from the ImageJ software protein profiling 
analysis revealing spot signal densities of various apoptotic protein concentration, the following 
histogram were produced, where a visual comparison between positive, negative and treatment 






Figure 5. Expression of Pro-apoptotic and Anti-apoptotic Proteins in APC-Mutant Breast Cancer 
Cell lines (A) MDA-MB-157, (B) 93A, (C) 93B from spot signal densities obtained through 
ImageJ software (NIH) data from Figure 4. Green box highlights significant pro-apoptotic 




Fluorescence results revealed that aqueous extract of S. barbata induced a statistically 
significant percentage of apoptosis in the three breast cancer cell lines when the negative and 
treatment groups were compared after both 1-hour and 3-hour incubation periods. Taking said 
results into consideration, we can conclude that S. barbata modulates apoptotic mechanism when 
added as a treatment.  
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Human Apoptosis Antibody Array protein profiling results demonstrated that there was a 
statistically significant difference between groups in the expression of pro-apoptotic proteins. 
Both BIM, and IGFBP-4 were significantly modulated in all breast cancer cell lines. BIM is a 
peptide found to induce cytochrome c release from mitochondria in vitro triggering apoptosis by 
binding and inactivating the antiapoptotic BCL2 relatives. (Tzifi et al., 2012). Similarly, IGFBP-
4 is an IGF binding proteins well known for its growth inhibitory effect (Durai et al., 2007). Both 
proteins very important in the cellular apoptotic pathways. Cell line 93A expressed the highest 
protein signal intensity for pro-apoptotic proteins with treatment in comparison to MDA-MB 157 
and 93B, leading us to conclude that S. barbata had a greater effect on cell line 93A. Taking into 
consideration that 93A is an APC mutant, genetically modified to be more resistant to treatment 
(VanKlompenberg, M. K., et al, 2004), results show high hope for treatment effectiveness in 
normal breast cancer cell. Even though 93B results showed that almost all proteins had p<0.05, 
values are not relievable. This is due to the fact that during experimentation a handling error was 
performed, causing a fold to form in the membrane and producing a band, which caused for 
values to be skewed; this can be seen both in the one-way ANOVA (Table 4) as well as the 
histogram for cell line 93B (Figure 7); where negative control group had the greatest protein 
expression even though only water was added.  
Even though both pro-apoptotic and anti-apoptotic proteins were tested through the 
experimental procedure, in this study only the analysis of the pro-apoptotic proteins among the 
three cell lines was performed. Future experimentation by the Phytochemical and 
Chemoprevention Research Lab in the Biology department will focus on analyzing how the anti-
apoptotic proteins were modulated by S. barbata. 
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Overall, results suggest that S. barbata contains phytochemicals that induce apoptosis in 
breast cancer cell lines MDA-MB-157, 93A, and 93B by modulating pro-apoptotic proteins; the 
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